JPWO2020210067A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210067A5 JPWO2020210067A5 JP2021559535A JP2021559535A JPWO2020210067A5 JP WO2020210067 A5 JPWO2020210067 A5 JP WO2020210067A5 JP 2021559535 A JP2021559535 A JP 2021559535A JP 2021559535 A JP2021559535 A JP 2021559535A JP WO2020210067 A5 JPWO2020210067 A5 JP WO2020210067A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 438
- 210000004027 cells Anatomy 0.000 claims description 56
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 44
- 102000038129 antigens Human genes 0.000 claims description 44
- 108091007172 antigens Proteins 0.000 claims description 44
- 229920000023 polynucleotide Polymers 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 25
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 21
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 21
- 102100013694 DLL3 Human genes 0.000 claims description 18
- 101700003144 DLL3 Proteins 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 12
- 206010018338 Glioma Diseases 0.000 claims description 12
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 12
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 12
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 12
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 12
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 12
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 206010017758 Gastric cancer Diseases 0.000 claims description 6
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 6
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 6
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 6
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 6
- 210000003932 Urinary Bladder Anatomy 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 201000009251 multiple myeloma Diseases 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 230000000955 neuroendocrine Effects 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drugs Drugs 0.000 claims description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 4
- 210000004693 NK cell Anatomy 0.000 claims description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 231100000486 side effect Toxicity 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002463 transducing Effects 0.000 claims description 3
- 108010071919 Bispecific Antibodies Proteins 0.000 claims description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 102000004965 antibodies Human genes 0.000 claims description 2
- 108090001123 antibodies Proteins 0.000 claims description 2
- 230000000711 cancerogenic Effects 0.000 claims description 2
- 230000000139 costimulatory Effects 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 230000002934 lysing Effects 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 230000001502 supplementation Effects 0.000 claims description 2
- 210000004881 tumor cells Anatomy 0.000 claims description 2
- 206010024324 Leukaemias Diseases 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 230000000527 lymphocytic Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002955 isolation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830598P | 2019-04-08 | 2019-04-08 | |
| US62/830,598 | 2019-04-08 | ||
| US201962861377P | 2019-06-14 | 2019-06-14 | |
| US62/861,377 | 2019-06-14 | ||
| US201962896790P | 2019-09-06 | 2019-09-06 | |
| US62/896,790 | 2019-09-06 | ||
| US201962928615P | 2019-10-31 | 2019-10-31 | |
| US62/928,615 | 2019-10-31 | ||
| PCT/US2020/025643 WO2020210067A1 (en) | 2019-04-08 | 2020-03-30 | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526420A JP2022526420A (ja) | 2022-05-24 |
| JPWO2020210067A5 true JPWO2020210067A5 (fi) | 2022-06-15 |
Family
ID=72750831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559535A Pending JP2022526420A (ja) | 2019-04-08 | 2020-03-30 | ヒト化抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184127A1 (fi) |
| EP (1) | EP3952888A1 (fi) |
| JP (1) | JP2022526420A (fi) |
| KR (1) | KR20210150432A (fi) |
| CN (1) | CN113795262A (fi) |
| AU (1) | AU2020271012A1 (fi) |
| BR (1) | BR112021016272A2 (fi) |
| CA (1) | CA3132202A1 (fi) |
| IL (1) | IL286984A (fi) |
| MX (1) | MX2021012336A (fi) |
| SG (1) | SG11202108759SA (fi) |
| WO (1) | WO2020210067A1 (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3148740A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| TW202302650A (zh) * | 2021-05-08 | 2023-01-16 | 大陸商上海齊魯製藥研究中心有限公司 | 針對dll3的結合分子及其應用 |
| CN114790240B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | SARS-CoV-2中和性单克隆抗体及应用 |
| WO2024044779A2 (en) * | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522716B (zh) * | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| CA2775573A1 (en) * | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
| TR201806936T4 (tr) * | 2010-01-29 | 2018-06-21 | Chugai Pharmaceutical Co Ltd | Anti-dll3 antikoru. |
| WO2011146514A2 (en) * | 2010-05-17 | 2011-11-24 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| AU2012293720A1 (en) * | 2011-08-05 | 2014-02-27 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Constitutively active uPAR variants and their use for the generation and isolation of inhibitory antibodies |
| RU2014138474A (ru) * | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| CN103173413A (zh) * | 2012-12-07 | 2013-06-26 | 天津三箭生物技术有限公司 | 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US9879087B2 (en) * | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TW202346349A (zh) * | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Dll3及cd3抗體構築體 |
| US20230140802A1 (en) * | 2017-09-27 | 2023-05-04 | University Of Southern California | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy |
-
2020
- 2020-03-30 BR BR112021016272A patent/BR112021016272A2/pt not_active Application Discontinuation
- 2020-03-30 US US17/593,087 patent/US20220184127A1/en active Pending
- 2020-03-30 AU AU2020271012A patent/AU2020271012A1/en not_active Abandoned
- 2020-03-30 JP JP2021559535A patent/JP2022526420A/ja active Pending
- 2020-03-30 MX MX2021012336A patent/MX2021012336A/es unknown
- 2020-03-30 EP EP20788157.4A patent/EP3952888A1/en not_active Withdrawn
- 2020-03-30 CA CA3132202A patent/CA3132202A1/en active Pending
- 2020-03-30 CN CN202080027518.8A patent/CN113795262A/zh active Pending
- 2020-03-30 WO PCT/US2020/025643 patent/WO2020210067A1/en unknown
- 2020-03-30 KR KR1020217034403A patent/KR20210150432A/ko unknown
- 2020-03-30 SG SG11202108759S patent/SG11202108759SA/en unknown
-
2021
- 2021-10-05 IL IL286984A patent/IL286984A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI564306B (zh) | 雙特異性抗體 | |
| US7498142B2 (en) | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| WO2019042119A1 (zh) | 抗人cd47抗体及其用途 | |
| JPWO2019173420A5 (fi) | ||
| JP2019531084A5 (fi) | ||
| JP2020528750A5 (fi) | ||
| JP2018524284A (ja) | 抗ｒｏｒ１抗体 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2009545325A5 (fi) | ||
| WO2012076066A1 (en) | Anti-ror1 antibodies and uses thereof | |
| JP2013527761A5 (fi) | ||
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| TW202033218A (zh) | 多特異性蛋白分子 | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JPWO2019224711A5 (fi) | ||
| CN109912716B (zh) | 一种egfr抗体及其制备方法和应用 | |
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| Watanabe et al. | In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody | |
| JPWO2020210067A5 (fi) | ||
| JPWO2019217145A5 (fi) | ||
| JPWO2020205331A5 (fi) | ||
| JPWO2020210247A5 (fi) | ||
| Takagi‐Maeda et al. | Novel cancer‐specific epidermal growth factor receptor antibody obtained from the serum of esophageal cancer patients with long‐term survival |